Study: HPV Vaccine Syndrome – 93% of Girls are Incapacitated
Updated: 17 January 2016
By: TLB Staff Writer: Leslie Carol Botha
Holy Hormones Journal: The tide is turning but the damage is done. A generation of adolescents maimed. Slowly, but surely, the researchers are beginning to do independent studies like the recent abstract on the government’s web site. A small survey of 45 girls in 13 countries and 93% continue to experience “incapacitating” symptoms that has left them unable to return to work or school. A random study and 93% incapacitated. The numbers are getting to high to deny. Except of course Murky Mercury Merck will deny until the go to court again.
Will they have the courage to do a study on 100 girls or 1,000 girls? Will the findings bear out the 93%?
Unfortunately, what is most likely occurring is “mutagenesis” and “carcinogenesis.” There may be a mechanism of action with the vaccine that is allowing these deviant pathologies to integrate into host cells causing mutations that make the body attack itself and/or causing the initial cell mutations that institute the onset of cancers. The group SANE Vax, who I was a part of many years ago – when they used a professional lab to test vials and lots of the HPV vaccine from different manufacturers from around the world. What was found was a recombinant (classified bio-hazard) HPV DNA in the vials. No one knows the effect that this recombinant DNA will have on host cell with ‘normal’ DNA. More frightening is that studies have not been done on how to rid the body of the bio-hazard. (Gardasil: Dr. Polansky Explains How Foreign DNA Fragments found in the Vaccine can Cause Disease)
HPV vaccination syndrome. A questionnaire-based study.
Martínez-Lavín M, et al. Clin Rheumatol. 2015.
Show full citation
Abstract
Isolated cases and small series have described the development of complex regional pain syndrome, postural orthostatic tachycardia, and fibromyalgia after human papillomavirus (HPV) vaccination. These illnesses are difficult to diagnose and have overlapping clinical features. Small fiber neuropathy and dysautonomia may play a major role in the pathogenesis of these entities. We used the following validated questionnaires to appraise the chronic illness that might appear after HPV vaccination: The 2010 American College of Rheumatology Fibromyalgia Diagnostic Criteria, COMPASS 31 dysautonomia questionnaire, and S-LANSS neuropathic pain form. These questionnaires and a “present illness” survey were e-mailed to persons who had the onset of a chronic ailment soon after HPV vaccination. Forty-five filled questionnaires from individuals living in 13 different countries were collected in a month’s period. Mean (±SD) age at vaccination time was 14 ± 5 years. Twenty-nine percent of the cases had immediate (within 24 h) post-vaccination illness onset. The most common presenting complaints were musculoskeletal pain (66 %), fatigue (57 %), headache (57 %), dizziness/vertigo (43 %), and paresthesias/allodynia (36 %). Fifty-three percent of affected individuals fulfill the fibromyalgia criteria. COMPASS-31 score was 43 ± 21, implying advanced autonomic dysfunction. Eighty-three percent of the patients who had ongoing pain displayed S-LANSS values >12, suggesting a neuropathic component in their pain experience. After a mean period of 4.2 ± 2.5 years post-vaccination, 93 % of patients continue to have incapacitating symptoms and remain unable to attend school or work. In conclusion, a disabling syndrome of chronic neuropathic pain, fatigue, and autonomic dysfunction may appear after HPV vaccination.
PMID
26354426 [PubMed – as supplied by publisher]
Read more here…
Abstract
Isolated cases and small series have described the development of complex regional pain syndrome, postural orthostatic tachycardia, and fibromyalgia after human papillomavirus (HPV) vaccination. These illnesses are difficult to diagnose and have overlapping clinical features. Small fiber neuropathy and dysautonomia may play a major role in the pathogenesis of these entities. We used the following validated questionnaires to appraise the chronic illness that might appear after HPV vaccination: The 2010 American College of Rheumatology Fibromyalgia Diagnostic Criteria, COMPASS 31 dysautonomia questionnaire, and S-LANSS neuropathic pain form. These questionnaires and a "present illness" survey were e-mailed to persons who had the onset of a chronic ailment soon after HPV vaccination. Forty-five filled questionnaires from individuals living in 13 different countries were collected in a month's period. Mean (±SD) age at vaccination time was 14 ± 5 years. Twenty-nine percent of the cases had immediate (within 24 h) post-vaccination illness onset. The most common presenting complaints were musculoskeletal pain (66 %), fatigue (57 %), headache (57 %), dizziness/vertigo (43 %), and paresthesias/allodynia (36 %). Fifty-three percent of affected individuals fulfill the fibromyalgia criteria. COMPASS-31 score was 43 ± 21, implying advanced autonomic dysfunction. Eighty-three percent of the patients who had ongoing pain displayed S-LANSS values >12, suggesting a neuropathic component in their pain experience. After a mean period of 4.2 ± 2.5 years post-vaccination, 93 % of patients continue to have incapacitating symptoms and remain unable to attend school or work. In conclusion, a disabling syndrome of chronic neuropathic pain, fatigue, and autonomic dysfunction may appear after HPV vaccination.
10% of those harmed by cervical cancer vaccines failing to recover
The Japan Time News September 2015
About 10 percent of those harmed by the cervical cancer vaccines Cervarix and Gardasil haven’t recovered yet, the health ministry has learned, adding that the June 2013 moratorium on promoting the drugs will stay in place.
According to a ministry survey of 1,739 patients, 186 were still experiencing side effects including headaches, fatigue and muscle weakness since being vaccinated, ministry officials said. Some of them lost their ability to walk.
In 135 of the cases, the problems are so severe they interfere with daily activities, including school and work.
Health minister Yasuhisa Shiozaki said Friday that the ministry is planning to begin research on why the side effects occur and potential treatments for them.
NHK reported that the ministry will also begin screening applications filed for medical benefits, but only in cases where a clear link exists or cannot be denied.
The drugs in question are Cervarix, made by GlaxoSmithKlein PLC, and Gardasil, a Merck Sharp & Dohme Corp. product. They inoculate against the human papillomavirus, which is believed to be the main cause of cervical cancer.
Vaccination is believed to have a 50 to 70 percent success rate against the virus. It requires three injections into the upper arm or thigh within six months.
Some 3.38 million people were vaccinated between December 2009, when the drugs were launched, and November 2014.
According to the survey, 2,584, or 0.08 percent, of the recipients suffered side effects, a rate higher than for the diphtheria, tetanus, pertussis and polio combination vaccines or Japanese encephalitis vaccines.
Read full article…
RELATED ARTICLES
Vaccine. 2012 May 14;30(23):3383-8. doi: 10.1016/j.vaccine.2012.03.065. Epub 2012 Apr 3.
Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model.
Abstract
INTRODUCTION:
Estimates of human papillomavirus (HPV) vaccine impact in clinical trials and modelling studies rely on DNA tests of cytology or biopsy specimens to determine the HPV type responsible for a cervical lesion. DNA of several oncogenic HPV types may be detectable in a specimen. However, only one type may be responsible for a particular cervical lesion. Misattribution of the causal HPV type for a particular abnormality may give rise to an apparent increase in disease due to non-vaccine HPV types following vaccination (“unmasking”).
Gardasil: Dr. Polansky Explains How Foreign DNA Fragments found in the Vaccine can Cause Disease
HPV Vaccine Injury Spreads like a Virus across the World
Legal Action to Challenge Cervical Cancer Vaccine in Schools
Cervical cancer vaccine reactions stand out in Japan
Author: Leslie Carol Botha
Author, publisher, radio talk show host and internationally recognized expert on women’s hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of “Understanding Your Mood, Mind and Hormone Cycle.” Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.
TLB Recommends you visit Leslie at her great website:
HOLY HORMONES JOURNAL The Greatest Story never Told
Source: The Liberty Beacon
Disclaimer: This article is not intended to provide medical advice, diagnosis, or treatment. Views expressed here do not necessarily reflect those of Gardasil Awareness NZ or their volunteers.
Comentários